Partnership Will Provide Cell and Gene
Therapy Industry with Fully Integrated Logistics
and Manufacturing Services for Regenerative Medicine
Products
NASHVILLE, Tenn. and YOKOHAMA, Japan, June 20,
2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)
("Cryoport"), a global leader in supply chain solutions for the
life sciences, and Minaris Regenerative Medicine Co., Ltd.
("Minaris"), a global contract development and manufacturing
organization for cell and gene therapies, today announced a
strategic partnership to provide fully integrated logistics and
manufacturing services to biotechnology and pharmaceutical
companies for regenerative medicine products to support the
advancement of cell and gene therapies.
The collaboration combines Cryoport's extensive capabilities and
experience in meeting the logistics needs of the life sciences
industry and Minaris' expertise in contract manufacturing of
regenerative medicine products including stem cells, gene therapy,
biomaterials and engineered tissue.
Jerrell Shelton, CEO of Cryoport,
commented, "We look forward to partnering with Minaris to provide
cohesive supply chain solutions and manufacturing services for
regenerative medicine products, starting from the collection of
cells and tissues all the way to the delivery of these critical
products and services to patients. This partnership perfectly
aligns with our organization's commitment to support the medical
community and the people it serves."
Dr. Hiroto Bando, CEO of Minaris,
added, "Ensuring secure transport, including the use and operation
of specialized containers, as well as quality assurance, is
essential for regenerative medicine products. By partnering with
Cryoport, a best-in-class company that has considerable resources
in all these areas, we will collaborate to provide high-quality
services tailored to the exact needs of our customers. While this
partnership is with Minaris' Japan-based branch, we will collaborate to
ensure that we can provide services to customers across the entire
Minaris group."
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is
a global leader in supply chain solutions for cell & gene
therapies that enable manufacturers, contract manufacturers
(CDMO's), contract research organizations (CRO's), developers, and
researchers to carry out their respective business with certainty.
We provide a broad array of supply chain solutions for the life
sciences industry. Through our platform of critical products and
solutions including advanced temperature-controlled packaging,
informatics, specialized bio-logistics services, bio-storage,
bio-services, and cryogenic systems, we are "Enabling the Future of
Medicine™" worldwide, through our innovative systems, compliant
procedures, and agile approach to superior supply chain
management.
Its corporate headquarters, located in Nashville, Tennessee, is complimented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Portugal,
Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
About Minaris Regenerative Medicine Co., Ltd.
Minaris
Regenerative Medicine is a global contract development and
manufacturing organization (CDMO) for cell and gene therapies. Our
vision is creating future cell therapy miracles together and we are
committed to providing global manufacturing services, development
solutions, and technologies for cell and gene therapies to improve
society's well-being. We offer our clients high value clinical and
commercial manufacturing services, development solutions, and
technologies. We are pioneers in the field with more than 25 years'
experience providing outstanding quality and reliability. Our
facilities in North America,
Europe, and Asia allow us to supply patients worldwide
with life-changing therapies. Minaris Regenerative Medicine is
wholly owned by Resonac Holdings Corporation.
For more information about Minaris, please visit
https://www.rm.minaris.com/en/
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to
Cryoport's industry, business, long-term growth prospects, plans,
strategies, acquisitions, future financial results and financial
condition, such as Cryoport's outlook and guidance for full year
2024 revenue and the related assumptions and factors expected to
drive revenue, projected growth trends in the markets in which the
Cryoport operates, Cryoport's plans and expectations regarding the
launch of new products and services, such as the expected timing
and benefits of such products and services launches, Cryoport's
expectations about future benefits of its acquisitions, and
anticipated regulatory filings, approvals, label/geographic
expansions or moves to earlier lines of treatment approved with
respect to the products of Cryoport's clients. Forward-looking
statements also include those related to Cryoport's anticipation
that its revenue will progressively improve throughout the year,
including anticipated acceleration of revenue from the Cryoport's
Cell & Gene Therapy clients, Cryoport's expectations that MVE's
cryogenic system sales will be challenged throughout the remainder
of the year, the Cryoport's expectations of the long-term prospects
of its Life Sciences Products business, including the anticipation
of demand normalizing, which would allow Cryoport to benefit from
its position as the global leader in this space, and Cryoport's
planned initiatives to drive toward positive adjusted EBITDA and
cash flow in the near term, which it expects should positively
impact its results of operations for the second half of 2024. It is
important to note that Cryoport's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic and geopolitical conditions,
supply chain constraints, inflationary pressures, the effects of
foreign currency fluctuations, trends in the products markets,
variations in Cryoport's cash flow, market acceptance risks, and
technical development risks. Cryoport's business could be affected
by other factors discussed in Cryoport's SEC reports, including in
the "Risk Factors" section of its most recently filed periodic
reports on Form 10-K and Form 10-Q, as well as in its subsequent
filings with the SEC. The forward-looking statements contained in
this press release speak only as of the date hereof and Cryoport
cautions investors not to place undue reliance on these
forward-looking statements. Except as required by law, Cryoport
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-and-minaris-regenerative-medicine-form-strategic-partnership-to-support-advancement-of-cell-and-gene-therapies-302177700.html
SOURCE Cryoport, Inc.